» Articles » PMID: 35145232

Intratumor Genetic Heterogeneity and Clonal Evolution to Decode Endometrial Cancer Progression

Abstract

Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored in endometrial carcinoma (EC). In this study, we sought to characterize the spatial and temporal heterogeneity of 9 different ECs using whole-exome sequencing, and by performing targeted sequencing validation of the 42 primary tumor regions and 30 metastatic samples analyzed. In addition, copy number alterations of serous carcinomas were assessed by comparative genomic hybridization arrays. From the somatic mutations, identified by whole-exome sequencing, 532 were validated by targeted sequencing. Based on these data, the phylogenetic tree reconstructed for each case allowed us to establish the tumors' evolution and correlate this to tumor progression, prognosis, and the presence of recurrent disease. Moreover, we studied the genetic landscape of an ambiguous EC and the molecular profile obtained was used to guide the selection of a potential personalized therapy for this patient, which was subsequently validated by preclinical testing in patient-derived xenograft models. Overall, our study reveals the impact of analyzing different tumor regions to decipher the ITGH in ECs, which could help make the best treatment decision.

Citing Articles

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application.

Casas-Arozamena C, Vilar A, Cueva J, Arias E, Sampayo V, Diaz E J Exp Clin Cancer Res. 2024; 43(1):264.

PMID: 39304963 PMC: 11414036. DOI: 10.1186/s13046-024-03158-w.


Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors.

Moreno-Moreno E, Caniego-Casas T, Carretero-Barrio I, Cortes A, Muriel A, Dominguez-Rullan J Am J Surg Pathol. 2024; .

PMID: 39269025 PMC: 11556818. DOI: 10.1097/PAS.0000000000002308.


Endometrial cancer at recurrence: To re-sequence or not to re-sequence.

Fuh K, Manning-Geist B Gynecol Oncol Rep. 2024; 53:101414.

PMID: 38841264 PMC: 11150684. DOI: 10.1016/j.gore.2024.101414.


The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence.

Buchynska L, Gordiienko I, Glushchenko N, Iurchenko N PLoS One. 2024; 19(4):e0302075.

PMID: 38669256 PMC: 11051633. DOI: 10.1371/journal.pone.0302075.


Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium.

Gatius S, Matias Guiu X, Davidson B Virchows Arch. 2023; 484(2):339-351.

PMID: 38099957 DOI: 10.1007/s00428-023-03710-7.


References
1.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

2.
Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

3.
Lax S, Kurman R . A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol. 1997; 81:228-32. View

4.
Kandoth C, Schultz N, Cherniack A, Akbani R, Liu Y, Shen H . Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447):67-73. PMC: 3704730. DOI: 10.1038/nature12113. View

5.
Soslow R . Endometrial carcinomas with ambiguous features. Semin Diagn Pathol. 2011; 27(4):261-73. DOI: 10.1053/j.semdp.2010.09.003. View